<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04392284</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-12345678</org_study_id>
    <nct_id>NCT04392284</nct_id>
  </id_info>
  <brief_title>Developing an Obesity Treatment Program in Family Medicine Clinics</brief_title>
  <official_title>Using the Multiphase Optimization Strategy Framework to Develop an Obesity Treatment Program in Family Medicine Clinics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the feasibility of conducting a multicomponent
      obesity treatment research study within the UAB Family Medicine Clinic at Highlands and to
      obtain preliminary data on the effectiveness of the intervention components. The research
      project will follow the Multiphase Optimization Strategy (MOST) framework to refine and
      screen intervention components for inclusion in a multicomponent obesity treatment program
      that could be delivered in family medicine clinics. The components to be investigated in the
      current study are 1) delivery type, 2) referral and membership at local YMCA, and 3)
      prescription of metformin . This study will use a 2x2x2 factorial design to investigate the
      main effects of each component in accordance with guidelines for using the MOST framework in
      clinical trials.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>2x2x2 factorial design using the Multiphase Optimization Strategy framework.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of recruitment and retention</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of participants recruited and retained in intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of recruitment and retention</measure>
    <time_frame>Month 3</time_frame>
    <description>Number of participants recruited and retained in intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of recruitment and retention</measure>
    <time_frame>Month 6</time_frame>
    <description>Number of participants recruited and retained in intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Family medicine clinician referral rates</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Family medicine clinician referral rates</measure>
    <time_frame>Month 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Family medicine clinician referral rates</measure>
    <time_frame>Month 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of counseling sessions attended</measure>
    <time_frame>Month 3</time_frame>
    <description>Attendance to in-person or Zoom meetings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of counseling sessions attended</measure>
    <time_frame>Month 6</time_frame>
    <description>Attendance to in-person or Zoom meetings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of visits to YMCA (as applicable)</measure>
    <time_frame>Month 3</time_frame>
    <description>Usage of provided YMCA membership</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of visits to YMCA (as applicable)</measure>
    <time_frame>Month 6</time_frame>
    <description>Usage of provided YMCA membership</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of metformin adherence (as applicable)</measure>
    <time_frame>Month 3</time_frame>
    <description>Number of times metformin was taken as prescribed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of metformin adherence (as applicable)</measure>
    <time_frame>Month 6</time_frame>
    <description>Number of times metformin was taken as prescribed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intervention preference</measure>
    <time_frame>Baseline</time_frame>
    <description>Preference is determined by the Intervention Preference Questionnaire, using a 5-point Likert Scale for preference among study treatment arms. Scale includes options for &quot;strong,&quot; &quot;slight,&quot; or &quot;no&quot; preference for a given treatment component.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intervention preference</measure>
    <time_frame>Month 3</time_frame>
    <description>Preference is determined by the Intervention Preference Questionnaire, using a 5-point Likert Scale for preference among study treatment arms. Scale includes options for &quot;strong,&quot; &quot;slight,&quot; or &quot;no&quot; preference for a given treatment component.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intervention preference</measure>
    <time_frame>Month 6</time_frame>
    <description>Preference is determined by the Intervention Preference Questionnaire, using a 5-point Likert Scale for preference among study treatment arms. Scale includes options for &quot;strong,&quot; &quot;slight,&quot; or &quot;no&quot; preference for a given treatment component.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment credibility</measure>
    <time_frame>Baseline</time_frame>
    <description>Assessment of participants' perception of treatment success using the Credibility/Expectancy Questionnaire with a 9-point Likert scale, ranging from &quot;not at all&quot; (1) to &quot;very&quot; (9) for several descriptors (e.g., &quot;useful,&quot; &quot;logical.&quot;)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment credibility</measure>
    <time_frame>Month 3</time_frame>
    <description>Assessment of participants' perception of treatment success using the Credibility/Expectancy Questionnaire with a 9-point Likert scale, ranging from &quot;not at all&quot; (1) to &quot;very&quot; (9) for several descriptors (e.g., &quot;useful,&quot; &quot;logical.&quot;)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment credibility</measure>
    <time_frame>Month 6</time_frame>
    <description>Assessment of participants' perception of treatment success using the Credibility/Expectancy Questionnaire with a 9-point Likert scale, ranging from &quot;not at all&quot; (1) to &quot;very&quot; (9) for several descriptors (e.g., &quot;useful,&quot; &quot;logical.&quot;)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in body weight</measure>
    <time_frame>Baseline to Months 3 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in body composition (fat and lean mass)</measure>
    <time_frame>Baseline to Months 3 and 6</time_frame>
    <description>Fat mass and lean mass via bioelectrical impedance analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glucose</measure>
    <time_frame>Baseline to Months 3 and 6</time_frame>
    <description>Serum glucose will be measured in a fasted state and after a glucose load [mg/dL]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in insulin</measure>
    <time_frame>Baseline to Months 3 and 6</time_frame>
    <description>Serum insulin will be measured in a fasted state and after a glucose load [uU/mL]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hemoglobin A1C</measure>
    <time_frame>Baseline to Months 3 and 6</time_frame>
    <description>Percentage (%) glycated hemoglobin as a measure of long-term blood glucose control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lipids</measure>
    <time_frame>Baseline to Months 3 and 6</time_frame>
    <description>Fasting serum concentrations of total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Obesity</condition>
  <condition>PreDiabetes</condition>
  <condition>Diabetes</condition>
  <condition>Hypertension</condition>
  <condition>Dyslipidemias</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>In-Person/Community Fitness/Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In-person delivery of weight loss intervention with community fitness membership and metformin prescription.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>In-Person/Community Fitness/No Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In-person delivery of weight loss intervention with community fitness membership.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>In-Person/No Community Fitness/Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In-person delivery of weight loss intervention with metformin prescription.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>In-Person/No Community Fitness/No Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In-person delivery of weight loss intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telehealth/Community Fitness/Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Online delivery of weight loss intervention with community fitness membership and metformin prescription.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telehealth/Community Fitness/No Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Online delivery of weight loss intervention with community fitness membership.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telehealth/No Community Fitness/Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Online delivery of weight loss intervention with metformin prescription.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telehealth/No Community Fitness/No Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Online delivery of weight loss intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>In-Person Delivery</intervention_name>
    <description>Delivery of weight loss intervention is conducted in person.</description>
    <arm_group_label>In-Person/Community Fitness/Metformin</arm_group_label>
    <arm_group_label>In-Person/Community Fitness/No Metformin</arm_group_label>
    <arm_group_label>In-Person/No Community Fitness/Metformin</arm_group_label>
    <arm_group_label>In-Person/No Community Fitness/No Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Telehealth</intervention_name>
    <description>Delivery of weight loss intervention is conducted online.</description>
    <arm_group_label>Telehealth/Community Fitness/Metformin</arm_group_label>
    <arm_group_label>Telehealth/Community Fitness/No Metformin</arm_group_label>
    <arm_group_label>Telehealth/No Community Fitness/Metformin</arm_group_label>
    <arm_group_label>Telehealth/No Community Fitness/No Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Community Fitness Membership</intervention_name>
    <description>Community fitness membership (local YMCA) is provided.</description>
    <arm_group_label>In-Person/Community Fitness/Metformin</arm_group_label>
    <arm_group_label>In-Person/Community Fitness/No Metformin</arm_group_label>
    <arm_group_label>Telehealth/Community Fitness/Metformin</arm_group_label>
    <arm_group_label>Telehealth/Community Fitness/No Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>No Community Fitness Membership</intervention_name>
    <description>No community fitness membership is provided.</description>
    <arm_group_label>In-Person/No Community Fitness/Metformin</arm_group_label>
    <arm_group_label>In-Person/No Community Fitness/No Metformin</arm_group_label>
    <arm_group_label>Telehealth/No Community Fitness/Metformin</arm_group_label>
    <arm_group_label>Telehealth/No Community Fitness/No Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Pill</intervention_name>
    <description>Metformin prescription is provided.</description>
    <arm_group_label>In-Person/Community Fitness/Metformin</arm_group_label>
    <arm_group_label>In-Person/No Community Fitness/Metformin</arm_group_label>
    <arm_group_label>Telehealth/Community Fitness/Metformin</arm_group_label>
    <arm_group_label>Telehealth/No Community Fitness/Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No Metformin</intervention_name>
    <description>No metformin prescription is provided.</description>
    <arm_group_label>In-Person/Community Fitness/No Metformin</arm_group_label>
    <arm_group_label>In-Person/No Community Fitness/No Metformin</arm_group_label>
    <arm_group_label>Telehealth/Community Fitness/No Metformin</arm_group_label>
    <arm_group_label>Telehealth/No Community Fitness/No Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  Any race or ethnicity

          -  BMI &gt;27 kg/m2

          -  Presence of 1 or more mild-to-moderate obesity-associated metabolic complications
             (i.e., Stage 1 Obesity) Prediabetes, type 2 diabetes (see exclusion criteria for
             additional details), metabolic syndrome, dyslipidemia, hypertension, non-alcoholic
             fatty liver disease

          -  Stable medication type and dosage for â‰¥3 months

        Exclusion Criteria:

          -  If type 2 diabetes, Currently prescribed metformin HbA1c concentration of &gt;12% Using
             exogenous insulin

          -  Pregnant or lactating within the past 6 months or trying to become pregnant

          -  Prescription for weight loss medications within the past 6 months

          -  Severe obesity-related complications that require immediate and more intensive
             clinical therapy (e.g., pharmacotherapy and/or bariatric surgery) as determined by
             study physician and/or referring practitioner at UAB Family Medicine Clinic.

          -  History of kidney disease that may increase the risk of lactic acidosis with
             metformin.

          -  Currently prescribed the following medications that may increase the risk of lactic
             acidosis with metformin: acetazolamide (Diamox), dichlorphenamide (Keveyis),
             methazolamide, topiramate (Topamax, in Qsymia), or zonisamide (Zonegran).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Drew Sayer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tapan Mehta, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gareth Dutton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline Cohen, PhD</last_name>
    <phone>2058738241</phone>
    <email>cwyoder@uab.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Drew Sayer, PhD</last_name>
    <email>sayerd@uab.edu</email>
  </overall_contact_backup>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 19, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Drew Sayer</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <keyword>weight loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

